Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Remitch OD Tablets Earns Indonesia Approval: Toray/Meiji Pharma
Toray and Meiji Seika Pharma said on September 26 that an OD tablet version of their oral pruritus treatment Remitch (nalfurafine) was granted regulatory approval in Indonesia in August. The approval allows the import and sale of Remitch OD for…
To read the full story
Related Article
- Remitch OD Tablets Approved in Thailand: Toray/Meiji Pharma
July 20, 2023
- Meiji Gets Thailand/Indonesia Rights to Toray’s Remitch
January 21, 2019
BUSINESS
- Pfizer, ASKA to Co-Promote RSV Vaccine Abrysvo in Japan
March 9, 2026
- Sumitomo to Launch Post-Marketing Study for iPSC Therapy by Year-End
March 9, 2026
- Drug Pricing Reform Draws Sharp Industry Backlash in Jiho Poll
March 9, 2026
- Nitrosamine Detected in Nichi-Iko’s Tryptanol, No Need to Halt Prescriptions
March 9, 2026
- Towa Broadens Label for Tacrolimus in Cell Transplantation
March 9, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…